Pimitespib by Otsuka Pharmaceutical for Metastatic Lung Cancer: Likelihood of Approval
Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Metastatic Lung Cancer. According to GlobalData,…
Pimitespib is under clinical development by Otsuka Pharmaceutical and currently in Phase I for Metastatic Lung Cancer. According to GlobalData, Phase I drugs for Metastatic Lung Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Pimitespib LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pimitespib overview
Pimitespib (Jeselhy) belongs to a class of antineoplastic drugs. It is formulated as tablets for oral route of administration. Jeselhy is indicated for the treatment of gastrointestinal stromal tumor (GIST) that has progressed after chemotherapy.
Pimitespib (TAS-116) is under development for the treatment of solid tumors including metastatic pancreatic cancer, metastatic biliary tract cancer, metastatic lung cancer, HER2 negative breast cancer, small cell lung cancer, endometrial cancer, bladder cancer and non-small cell lung carcinoma. It is a small molecule administered orally. It is a HSP90 inhibitor.
It was under development for gastric cancer,HER2+ breast cancer, thymic carcinoma and solid tumor
Otsuka Pharmaceutical overview
Otsuka Pharmaceutical (OPC), a subsidiary of Otsuka Holdings Co Ltd, is a manufacturer and supplier of pharmaceuticals, food products, clinical testing, and medical equipment. The company develops formulations for diagnosis and treatment of central nervous system, oncology, cardiovascular and renal, gastrointestinal, ophthalmology disorders and infectious diseases through its pharmaceutical business. It’s nutraceutical segment offers rehydration, nutrition, vitamin supplements and cosmetics. OPC is investigating drugs for psychiatry and neurology; oncology; cardiovascular and other therapeutic indications in collaboration with academia and venture companies. The company operates branch offices, research facilities and factories in Japan. OPC is headquartered in Chiyoda-ku, Tokyo, Japan.
For a complete picture of Pimitespib’s drug-specific PTSR and LoA scores, buy the report here.
What's Your Reaction?
